Commodore Capital
VC Fund
New York, United States
Commodore Capital is a VC fund in New York focused on Biotechnology and Therapeutics. Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.
- Total investments:
- 52
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Commodore Capital invests in
Stages Commodore Capital invests in
Countries Commodore Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Michael Kramarz
|
|||
Egen Atkinson
|
|||
|
Robert Glass
|
|||
Investment Focus
Industry
- Biotechnology 38 (73%)
- Therapeutics 25 (48%)
- Health Care 20 (38%)
- Pharmaceutical 11 (21%)
- Medical 10 (19%)
Stage
- Post-IPO Equity 32 (62%)
- Series B 5 (10%)
- Seed 2 (4%)
- Private Equity 2 (4%)
- Series A 1 (2%)
Country
- United States 39 (75%)
- Canada 2 (4%)
- France 1 (2%)
- United Kingdom 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Michael Kramarz
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 0 | Find email | |
|
Egen Atkinson
Co-Founder & Managing Partner
|
Co-Founder & Managing Partner | Total investments: 0 | Find email | |
|
Robert Glass
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
LB Pharmaceuticals
|
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $150M / Post-IPO Equity / Jul 29, 2026 | |
Mentari Therapeutics
|
Mentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine. | $200M / Private Equity / Jul 22, 2026 | |
Agenus
|
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers,vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing.It was established in 1994 and is headquartered in Lexington, Massachusetts. | $85M / Post-IPO Debt / Jul 13, 2026 | |
Ollin Biosciences
|
Ollin Biosciences operates as a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. | $330M / Series B / Jun 24, 2026 | |
Assembly Biosciences
|
Assembly Biosciences, Inc. is a public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral biotherapeutics designed to address diseases associated with the microbiome.Assembly‘s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform is in development for the treatment of C. difficile infections. Assembly is also developing additional microbiome product candidates. | $115M / Post-IPO Equity / May 22, 2026 | |
Alto Neuroscience
|
Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $120M / Post-IPO Equity / Mar 16, 2026 | |
Relmada Therapeutics
|
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor(NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults.() | $160M / Post-IPO Equity / Mar 09, 2026 | |
AN2 Therapeutics
|
AN2 Therapeutics, Inc. is a California-based global health biopharmaceutical company focused on modern biomedical and drug development expertise to provide transformational medicines for patients suffering from infectious diseases. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. | $40M / Post-IPO Equity / Mar 09, 2026 | |
|
LB Pharmaceuticals
|
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. Its approach is to create a research-focused organization dedicated to generating novel intellectual propertyaround improved versions of these former best-selling drugs. The Company's lead asset is LB-102 (n-Methyl amisulpride) a novel, patented version of amisulpride, one of the most effective drugs ever developed for the treatment of schizophrenia. | $100M / Post-IPO Equity / Feb 05, 2026 | |
Perspective Therapeutics
|
Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them. | $175M / Post-IPO Equity / Feb 02, 2026 | |
| See all 52 investments → | |||
Co-Investors
Deep Track Capital
18 deals together
RA Capital Management
17 deals together
Venrock Healthcare Capital Partners
17 deals together
Perceptive Advisors
16 deals together
Biotechnology Value Fund
14 deals together
Logos Capital
14 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Commodore Capital invest in?
Commodore Capital invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Post-IPO Equity and Series B stage. Most of the 52 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Commodore Capital?
Public channels for Commodore Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Commodore Capital?
The team at Commodore Capital includes Michael Kramarz (Co-Founder & Managing Partner), Egen Atkinson (Co-Founder & Managing Partner) and Robert Glass (Chief Financial Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
